- Home
- IDAI vs SBFM Comparison
IDAI vs SBFM Comparison
Compare IDAI & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- SBFM
- Stock Information
- Founded
- IDAI 2016
- SBFM 2006
- Country
- IDAI United States
- SBFM United States
- Employees
- IDAI N/A
- SBFM N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- IDAI Technology
- SBFM Health Care
- Exchange
- IDAI Nasdaq
- SBFM Nasdaq
- Market Cap
- IDAI 4.2M
- SBFM 3.7M
- IPO Year
- IDAI N/A
- SBFM N/A
- Fundamental
- Price
- IDAI $0.18
- SBFM $2.36
- Analyst Decision
- IDAI
- SBFM
- Analyst Count
- IDAI 0
- SBFM 0
- Target Price
- IDAI N/A
- SBFM N/A
- AVG Volume (30 Days)
- IDAI 2.7M
- SBFM 1.5M
- Earning Date
- IDAI 11-15-2024
- SBFM 11-05-2024
- Dividend Yield
- IDAI N/A
- SBFM N/A
- EPS Growth
- IDAI N/A
- SBFM N/A
- EPS
- IDAI N/A
- SBFM N/A
- Revenue
- IDAI $2,160,186.00
- SBFM $32,959,491.00
- Revenue This Year
- IDAI N/A
- SBFM $86.70
- Revenue Next Year
- IDAI $215.04
- SBFM $126.76
- P/E Ratio
- IDAI N/A
- SBFM N/A
- Revenue Growth
- IDAI N/A
- SBFM 61.94
- 52 Week Low
- IDAI $0.15
- SBFM $2.11
- 52 Week High
- IDAI $2.50
- SBFM $638.00
- Technical
- Relative Strength Index (RSI)
- IDAI 40.67
- SBFM 37.00
- Support Level
- IDAI $0.15
- SBFM $2.11
- Resistance Level
- IDAI $0.21
- SBFM $2.34
- Average True Range (ATR)
- IDAI 0.03
- SBFM 0.22
- MACD
- IDAI 0.00
- SBFM -0.03
- Stochastic Oscillator
- IDAI 29.78
- SBFM 27.22
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.